Home LiteratureArticle Details
PMID: 1709070 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Localization of 20-kD homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study.

Clinical and experimental immunology ·Vol. 84 ·No. 2 ·1991-05-00 ·Pages 256-62

Tamai H, Matsuo S, Fukatsu A, Nishikawa K, Sakamoto N, Yoshioka K, Okada N, Okada H

Abstract

The 20-kD homologous restriction factor (HRF20), which is identical to CD59, is a membrane-associated protein which inhibits the reaction of C9 to form membrane attack complex (MAC) of homologous complements. In various human glomerular diseases deposition of complement components is frequently seen and MAC is reported to associate with immune deposits. Using a specific monoclonal antibody, 1F5, against HRF20, we attempted to study the localization of HRF20 in human glomerulonephritides and to compare the localization of HRF20 with those of immune deposits and MAC. The frozen sections of kidney specimens were fixed in acetone at room temperature before staining. In normal kidneys and kidney specimens from the patients with minimal change nephrotic syndrome, membranous nephropathy, and IgA nephropathy, HRF20 was strongly localized in the peritubular capillaries and along Bowman's capsules. A weaker but well-defined staining was obtained in the mesangial area and faint staining was seen along the glomerular capillary walls. In contrast, glomerular capillary walls were rather strongly stained in the cases with diffuse lupus nephritis which had subendothelial dense deposits. These data suggest that HRF20 (CD59) is present in the human glomeruli and its expression is enhanced under certain conditions such as lupus nephritis.

MeSH Terms
Antigens, Differentiation/biosynthesis CD59 Antigens Complement C1q/analysis Complement C3/analysis Complement C4/analysis Fibrinogen/analysis Fluorescent Antibody Technique Glomerulonephritis, IGA/metabolism Glomerulonephritis, Membranous/metabolism Humans Immunoglobulin A/analysis Immunoglobulin G/analysis Immunoglobulin M/analysis Kidney Diseases/metabolism Kidney Glomerulus/metabolism Lupus Nephritis/metabolism Membrane Glycoproteins/biosynthesis Nephrosis, Lipoid/metabolism
Chemicals
Antigens, Differentiation CD59 Antigens Complement C3 Complement C4 Immunoglobulin A Immunoglobulin G Immunoglobulin M Membrane Glycoproteins Complement C1q Fibrinogen
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Tamai H
Third Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Matsuo S
Fukatsu A
Nishikawa K
Sakamoto N
Yoshioka K
Okada N
Okada H
References (37)
37 references, click to expand
  1. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement.
    Int Immunol. 1989;1(2):205-8 PMID: 2487685
  2. Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action.
    Immunochemistry. 1969 May;6(3):405-19 PMID: 5786934
  3. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.
    Biochem J. 1989 Nov 15;264(1):1-14 PMID: 2690818
  4. Membrane attack complex deposition in experimental glomerular injury.
    Am J Pathol. 1985 Jul;120(1):121-8 PMID: 3160245
  5. Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue.
    Am J Pathol. 1987 Apr;127(1):182-90 PMID: 2952015
  6. 20 KDa homologous restriction factor of complement resembles T cell activating protein.
    Biochem Biophys Res Commun. 1989 Aug 15;162(3):1553-9 PMID: 2475111
  7. Localization of decay accelerating factor in normal and diseased kidneys.
    Kidney Int. 1989 Jul;36(1):100-7 PMID: 2478749
  8. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.
    J Exp Med. 1989 Sep 1;170(3):637-54 PMID: 2475570
  9. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement.
    J Immunol. 1989 Oct 1;143(7):2262-6 PMID: 2476502
  10. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels.
    J Biochem. 1988 Oct;104(4):633-7 PMID: 2467907
  11. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.
    J Immunol. 1986 Mar 1;136(5):1772-6 PMID: 2419413
  12. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    J Clin Invest. 1989 Jul;84(1):7-17 PMID: 2738160
  13. The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus.
    Arthritis Rheum. 1988 Feb;31(2):188-95 PMID: 3348822
  14. Detection of terminal complement components in experimental immune glomerular injury.
    Kidney Int. 1984 Dec;26(6):830-7 PMID: 6241952
  15. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    J Exp Med. 1984 Nov 1;160(5):1558-78 PMID: 6238120
  16. Immunohistochemical study of the C5b-9 complex of complement in human kidneys.
    Kidney Int. 1986 Sep;30(3):399-410 PMID: 3537447
  17. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis.
    Kidney Int. 1987 Mar;31(3):820-9 PMID: 3573542
  18. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis.
    J Immunol. 1987 Jan 1;138(1):246-53 PMID: 3782799
  19. The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium.
    Biochem J. 1985 Oct 1;231(1):205-8 PMID: 4062885
  20. Role of terminal complement pathway in the heterologous phase of antiglomerular basement membrane nephritis.
    Kidney Int. 1985 Apr;27(4):643-51 PMID: 4010151
  21. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus.
    N Engl J Med. 1985 Jun 20;312(25):1594-9 PMID: 4000197
  22. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9.
    J Immunol. 1985 Mar;134(3):1804-9 PMID: 3968432
  23. Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo.
    Immunology. 1990 Jun;70(2):145-9 PMID: 1695609
  24. Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells.
    Immunology. 1990 Mar;69(3):396-401 PMID: 1690178
  25. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes.
    J Immunol. 1990 Mar 1;144(5):1823-8 PMID: 2307842
  26. The 1982 revised criteria for the classification of systemic lupus erythematosus.
    Arthritis Rheum. 1982 Nov;25(11):1271-7 PMID: 7138600
  27. Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes.
    Eur J Immunol. 1983 Apr;13(4):340-4 PMID: 6221932
  28. Membrane attack complex of complement as a pathologic mediator.
    Lab Invest. 1983 Sep;49(3):237-49 PMID: 6193330
  29. Elimination of complement channels from the plasma membranes of U937, a nucleated mammalian cell line: temperature dependence of the elimination rate.
    J Immunol. 1983 Sep;131(3):1411-5 PMID: 6309963
  30. Single channel currents induced by complement in antibody-coated cell membranes.
    Proc Natl Acad Sci U S A. 1981 Oct;78(10):6421-5 PMID: 6273870
  31. Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit.
    J Clin Invest. 1983 Dec;72(6):1948-57 PMID: 6227634
  32. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
    J Immunol. 1982 Jul;129(1):184-9 PMID: 6211481
  33. Localization of the membrane attack complex (MAC) in experimental immune complex glomerulonephritis.
    J Exp Med. 1983 Jun 1;157(6):1885-905 PMID: 6343549
  34. Retardation of fading and enhancement of intensity of immunofluorescence by p-phenylenediamine.
    J Histochem Cytochem. 1983 Jun;31(6):840-2 PMID: 6341464
  35. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease.
    J Clin Invest. 1983 Aug;72(2):560-73 PMID: 6348093
  36. Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis.
    J Exp Med. 1981 Dec 1;154(6):1779-94 PMID: 7033435
  37. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.
    Proc Natl Acad Sci U S A. 1986 Sep;83(18):6975-9 PMID: 2428045
Article Info
Journal
Clinical and experimental immunology
Abbr.
Clin Exp Immunol
ISSN
0009-9104
Published
1991-05-00
Pages
256-62
Language
English
Region
England
NLM ID
0057202
PMCID
PMC1535408
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com